Multimodal Imaging and EV-Omics Biomarkers for PSP

Günter Höglinger, Ludwig Maximilian University of Munich


Abstract:

Progressive supranuclear palsy (PSP) is a rare neurodegenerative diseases that is difficult to diagnose, especially in early stages. Patients are often misdiagnosed, and there are currently no reliable biological tests (biomarkers) to confirm the disease during life. This limits patient care, slows down clinical trials, and hampers the development of new treatments.

This project aims to develop new biomarkers by combining advanced brain imaging with innovative blood- and cerebrospinal fluid-based tests. Brain scans (PET imaging) can detect disease-related changes such as abnormal tau protein and inflammation, but they are expensive and not widely available. In contrast, tiny particles in blood and cerebrospinal fluid, called extracellular vesicles (EVs), can carry molecular information directly from brain cells. These EVs provide a unique and minimally invasive way to study disease processes.

We will analyze EVs from different brain cell types (neurons, astrocytes, and microglia) and measure disease-related proteins. These molecular signatures will then be linked to imaging findings in the same patients to better understand how blood-based markers reflect changes in the brain. Finally, we will validate our findings in an independent group of patients.

The goal is to develop a reliable and scalable biomarker panel that can improve diagnosis, allow better patient stratification in clinical trials, and potentially enable monitoring of disease progression or treatment response. By integrating imaging and fluid-based biomarkers, this project aims to bridge the gap between complex research tools and practical clinical applications.

Importantly, the project will also generate a publicly available resource of PSP-related EV molecular data, supporting future research and accelerating biomarker development in the field.